OncoTargets and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Prof. Dr. Hans-Joachim Schmoll
An international, peer-reviewed journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. In terms of therapy, palliative care is also included as part of the overall patient care process. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. This journal explores the evidence behind new and existing therapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
Journal Impact Factor: 1.261 (5 year impact 1.089)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
- PubMed (Onco Targets Ther)
- Directory of Open Access Journals (DOAJ)
- OAIster: The Open Access Initiative
- ResearchGATE scientific network
Article Processing Statistics:
25 From submission of manuscript to first editorial decision (including peer-review)
38 From editorial acceptance to publication
- ASCO 2013 Meet the Editor
We invite you to meet Prof Dr Hans-Joachim Schmoll at the Dove Medical Press booth 22102 on June 1st at 11am. Prof Dr Schmoll is the Editor-in-Chief of the journal OncoTargets and Therapy (IF 1.26).
- Have an opinion about one of our articles?
We encourage you to write a letter to the editor.